Stem cell biotech Orthocell has treated the first patient in a new study designed to show its “ATI” system can be used for shoulder injuries.

ATI stands for Autologous Tenocyte Implantation. It involves removing stem cells from a healthy tendon, expanding them in culture and then using them to repair damaged tendons in a different part of the body.

Orthocell (ASX:OCC)’s new study is to measure its performance against corticosteroid injections to treat rotator cuff tendinopathy and tear in the shoulder.

“We expect results to show Ortho-ATI is a durable and effective treatment for degenerate shoulder injuries,” Orthocell managing director Paul Anderson said.

The video below gives an overview of how Ortho-ATI works.

The study is being led by two professors at the Australian Elbow and Shoulder Society and the University of Western Australia, and is part of Orthocell’s collaboration deal with a subsidiary of healthcare giant Johnson and Johnson announced earlier this year.

Orthocell shares were down slightly, about 3 per cent, to 29c on Tuesday morning. They have traded between 28c and 54c over the past 12 months.